

PAR/CS/NSE/2026-27/11

Date: 08/08/2026

To,
The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051
Maharashtra

Subject: Outcome of the Board Meeting held on Saturday, 8th day of August, 2026 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015

Ref.: Symbol- PAR, ISIN: INE04LG01015

Dear Sir/Madam,

The meeting of Board of Directors of the Company held on **Saturday, 8th day of August, 2026 at 3:30 P.M.** through Video Conferencing ("VC") mode to transacted the following business:

Item No.	Outcomes
1.	After the recommendation of Audit Committee, the Board of Directors considered, approved and took on record the Unaudited Standalone Financial Results of the Company for the quarter ended on 30th June, 2026 along with Limited Review Report given CA Miral Mehta, Partner of Sarupria Somani & Associates, Chartered Accountants, Statutory Auditor of the Company. The Board authorised Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and Mr. Jignesh Vallabhbbhai Savani, CEO & Director (DIN: 00198203) to sign the approved financial results. The financial results were duly reviewed by Audit Committee at its meeting. Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Certificate of correctness was placed before the Board Meeting. (Limited Review Report with Financials statements and Certificate of Correctness are attached as Annexure)
2.	The Board considered and approved the drafts of advertisements to be published in newspapers regarding Unaudited Standalone Financial Results of the Company for the quarter ended on 30th June, 2026. The Board decided to publish the said advertisements in the Economic Times & Navgujarat Samay or as available.
3.	The Board took note of Investor grievances report for the quarter ended 30th June, 2026 and reviewed the SCORES platform of SEBI to solve the investor compliant till date.
4.	The Board took note and review the Corporate Governance Report of the Company for the quarter ended 30th June, 2026.
5.	After recommendation of Audit Committee, the Board considered and approved the Policy on Communication between Statutory Auditor and Those Charged with Governance (TCWG), which will be available at the website of the Company at www.pardrugs.com with due course.



With the permission and consent of the Chairman & all other Board members following other matter was taken and approved	
6.	By considering the suggestion of audit committee, the board has considered, discussed, approved to avail the forward booking Banking facilities by Company from ICICI Bank and authorized Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and/or Mr. Jignesh Vallabhbbhai Savani, CEO & Director (DIN: 00198203) of the Company to provide required resolution to the Bank and be and are hereby authorized to do sign and/digitally sign all such necessary forms, documents, papers, and to do all such acts, matters, deeds as may be required for the above mentioned purpose. Further, the Board authorised any of the director to provide required certified true copy of resolutions to give effect for the mentioned matter.
7.	By considering the suggestion of audit committee, the board has considered, discussed, approved to appoint NEO Alternative Asset Managers Private Limited (SEBI Registration No.: INP000007641) as a Portfolio Manager of the Company to avail Portfolio Management and other Services and to open demat account with them. The Board authorised Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and Mr. Jignesh Vallabhbbhai Savani, CEO & Director (DIN: 00198203) to sign and/digitally sign, execute all such necessary documents including application forms, agreements, undertakings, indemnities, Power of Attorney, documents, operate demat and/or give instruction to operate Demet on behalf of the Company and to do all such acts, deeds and things as may be necessary and incidental thereto for the purpose of giving effect. Further, the Board authorised any of the director to provide required certified true copy of resolutions to give effect for the mentioned matter.
8.	By considering the suggestion of audit committee, the Board of Directors has discussed and approved to sale of Motor Vehicle of Company at total of Rs 3.60 Lakh approx. and to purchase of New Motor Vehicles (i) Toyota Fortuner Legender 4X2 (AT) Diesel pearl white & black variant amounting of ex-showroom Price of Rs. 42.92 Lakh plus applicable taxes, insurance, accessories, warranties and others charges in the name of Par Drugs And Chemicals Limited for the use of Mr. Jignesh V. Savani ,Director & CEO (DIN: 00198203) of the Company. (ii) Mahindra XEV 9E PACK-3 B-79 ruby velvet variant amounting of ex-showroom Price of Rs. 29.43 Lakh plus applicable taxes, insurance, accessories, warranties and others charges in the name of Par Drugs And Chemicals Limited for the use of Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236). The Board authorised any of the current directors to sign and execute all such necessary forms, documents, agreement, papers, and to do all such acts, matters and deeds as may be required time to time for the sale & purchase of the motor vehicles.

Although all the submission is made by integrated financial in XBRL format, this intimation shall also be considered as Integrated Filing (Financial) for the quarter ended on 30th June, 2026 pursuant to Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

QUARTERLY INTEGRATED FILING (FINANCIAL)
FOR THE QUARTER ENDED JUNE 30, 2026

PARTICULARS	DISCLOSURE
A. FINANCIAL RESULTS	Enclosed



B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.	Not Applicable Reason of Non-Applicability: As there is no any proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.
C. OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES	Not Applicable Reason of Non-Applicability: As there is no any outstanding default on loans and debt securities.
D. DISCLOSURE OF RELATED PARTY TRANSACTIONS	Not Applicable Reason of Non-Applicability: As per above mentioned circular applicable only for half-yearly filings i.e 2 nd and 4 th quarter. Hence, not applicable for the Quarter ended June 30, 2026.
E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS	Not Applicable Reason of Non-Applicability: As per above mentioned circular applicable only for Annual Filing i.e., 4 th quarter. Hence, not applicable for the Quarter ended June 30, 2026.

Further, with reference to our intimation dated 25th June, 2026 and pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and amendment made time to time till date and according to Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the trading window for trading in securities of the Company will be opened after 48 hours of declaration of the attached financial result for Designated persons, Designated employees and their Immediate relatives i.e. to say for all insiders.

The Board Meeting was commenced at 03:30 PM and concluded at 5:10 PM.

Kindly take on the record and acknowledge the receipt.

Yours Faithfully,

For PAR DRUGS AND CHEMICALS LIMITED



(Sanket B. Trivedi)

Company Secretary & Compliance Officer

Annexure: Limited Review Report with Financials statements and Certificate of Correctness



Sarupria Somani & Associates Chartered Accountants

Partner : CA Miral Bipinbhai Mehta
B.Com, FCA

CA Miral B. Mehta
602, Victoria Corporate,
Opp. Gulista Ground, Sony Show
Room Lane, Vadodariya Park,
Bhavnagar. Gujarat-364001
Mobile : 9909366366
Email : somanibvn@gmail.com

Limited Review Report on standalone un-audited Quarterly financial results for the quarter ended 30th June, 2026 of Par Drugs and Chemicals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To,
The Board of Directors
Par Drugs and Chemicals Limited

We have reviewed the accompanying statement of unaudited financial results of **Par Drugs and Chemicals Limited** having its registered office at 815, Nilamber Triumph, Gotri Vasna Road, Vadodara, Gujarat-390007 for the quarter ended 30th June, 2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Our conclusion is not modified in respect of this matter.

SARUPRIA SOMANI & ASSOCIATES

(Firm Regn No. – 010674C)
CHARTERED ACCOUNTANTS



MIRAL MEHTA (Partner)

M.No.145361

Bhavnagar, 08th August, 2026

UDIN - 26145361QARESD2459



PAR DRUGS AND CHEMICALS LIMITED

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara-390007, Gujarat, India
Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com Website: www.pardrugs.com

Standalone Audited Financial Results for the Quarter Ended 30th June, 2026


Statement Of Profit & Loss

(Rs. in Lakhs)

	Particulars	Quarter Ended			Year to Date	
		30-06-2026	31-03-2026	30-06-2025	30-06-2026	31-03-2026
		Unaudited	Audited	Unaudited	Unaudited	Audited
I	Revenue from operations	3,128.05	1,961.08	2,604.64	3,128.05	10,365.56
II	Other income	93.53	35.85	183.67	93.53	400.07
III	Total Revenue (I + II)	3,221.58	1,996.93	2,788.31	3,221.58	10,765.63
IV	Expenses:					
	Cost of materials consumed	1,283.50	884.59	1,116.32	1,283.50	4,267.05
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	90.89	6.26	17.23	90.89	69.09
	Employee benefits expense	168.92	193.54	141.97	168.92	612.01
	Finance costs	2.14	4.14	1.63	2.14	12.73
	Depreciation and amortization expense	96.42	92.75	90.35	96.42	370.33
	Other expenses	946.70	732.50	973.04	946.70	3,704.26
	Total expenses (IV)	2,588.57	1,913.78	2,340.54	2,588.57	9,035.47
V	Profit / (loss) before exceptional items and tax (III-IV)	633.01	83.15	447.77	633.01	1,730.16
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00
VII	Profit / (loss) before tax (V - VI)	633.01	83.15	447.77	633.01	1,730.16
VIII	Tax expense:					
	(1) Current tax	161.74	31.39	114.97	161.74	452.90
	(2) Deferred tax	0.00	-33.60	0.00	0.00	-33.60
IX	Profit / (Loss) for the period from continuing operations (VII-VIII)	471.27	85.36	332.80	471.27	1,310.86
X	Profit / (loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX + XII)	471.27	85.36	332.80	471.27	1,310.86
XIV	Other Comprehensive Income					
	A (i) items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	B (i) items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
XV	Total Comprehensive Income for the period (comprising profit / (loss) and other comprehensive income for the period) (XIII + XIV)	471.27	85.36	332.80	471.27	1,310.86
XVI	Paid up Equity share capital (Face value of Rs. 10 each)	1,230.46	1,230.46	1,230.46	1,230.46	1,230.46
XVII	Reserves & Surplus excluding revaluation reserve	10,439.27	9,968.00	8,999.84	10,439.27	9,968.00
XVIII	Earnings per equity share (for discontinued operation)					
	(1) Basic	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00
XIV	Earnings per equity share (for discontinued & continuing operation) (EPS for 3 and 9 months ended periods are not annualised)					
	(1) Basic	3.83	0.69	2.70	3.83	10.65
	(2) Diluted	3.83	0.69	2.70	3.83	10.65


For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Mr. Jigneshbhai V. Savani
Director & CEO
(DIN - 00198203)



For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Mr. Falgun V. Savani
(Chairman & Managing Director)
(DIN - 00198236)



PAR DRUGS AND CHEMICALS LIMITED

(CIN : L24117GJ1999PLC035512)


Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com

Website: www.pardrugs.com

NOTES:

1. The standalone financial results of the Company have been prepared in accordance with the Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including relevant circulars issued by the SEBI from time to time.
2. The above quarterly and year to date financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 08th August, 2026.
3. The Statutory auditors of the company have carried out Limited Review of the above quarterly financial results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
4. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earning per share (not annualized) in accordance with the Ind AS.
5. Previous Year/Period figures are regrouped / reclassified / rearranged, whenever found necessary to make them comparable with the current period figures.
6. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on "Operating Segments". Accordingly, there are no separate reportable segments as per Ind AS - 108.
7. The Company does not have any subsidiary, associates or joint venture as on 30th June, 2026; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company.



PAR DRUGS AND CHEMICALS LIMITED

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com

Website: www.pardrugs.com

8. The above unaudited financial results of the Company are available on the Company's website – www.pardrugs.com and on the website of the National Stock Exchange of India Limited (www.nseindia.com), where the Company's shares are listed.


9. The Status of investors complaints are as follows:

I. Pending at the beginning of the quarter	-	0
II. Received during the quarter	-	0
III. Disposed-off during the quarter	-	0
IV. Remaining unresolved at the end of the quarter	-	0

For and on behalf of Board of Directors
Par Drugs and Chemicals Limited



Mr. Falgun V. Savani
(Chairman & Managing Director)
(DIN - 00198236)



For and on behalf of Board of Directors
Par Drugs and Chemicals Limited



Mr. Jignesh V. Savani
(Director & CEO)
(DIN - 00198203)



Vadodara, 08th August, 2026

To,
The Board of Directors
Par Drugs And Chemicals Limited

CERTIFICATE OF CORRECTNESS OF FINANCIAL RESULTS

Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that the financial results of the Company for the quarter ended on 30th June, 2026 placed before the meeting do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

For Par Drugs And Chemicals Limited

Date: 08/08/2026


Place: Bhavnagar



(Mr. Jignesh V. Savani)
Chief Executive Officer



For Par Drugs And Chemicals Limited



(Mr. Chintan P. Chauhan)
Chief Financial Officer

